Edward D. Ball

Director of the Blood and Marrow Transplant Program at the Moores UCSD Cancer Center. Dr. Ball completed fellowships in hematology and oncology at The Geisel School of Medicine at Dartmouth and University Hospitals Case Medical Center in Cleveland. He completed residency training at Hartford Hospital in Connecticut and earned his medical degree from Case Western Reserve University School of Medicine in Cleveland. He is board-certified in hematology, medical oncology and internal medicine.

A Professor in the Department of Medicine at UCSD, he is a highly respected cancer researcher who studies all aspects of stem cell transplantation and has patented four of his cancer treatment innovations. Dr. Ball has published over 250 journal articles and book chapters based on his basic and clinical research.

Dr Ball was one of the founders of Medarex, the company that has developed two of the most important FDA approved cancer immunotherapy drugs, ipilimumab (Yervoy) and nivolumab (Opdivo) and was later acquired by Bristol Myers Squibb. These are two of the three cancer immunotherapy drugs with the highest sales volume and the largest number of ongoing clinical trials in diverse oncology applications.